RetinalGenix Technologies (RTGN) Net Cash Flow (2020 - 2026)
RetinalGenix Technologies (RTGN) reported Net Cash Flow of -$14594.0 for Q1 2026, down 521.29% on a YoY basis from $3464.2 in Q1 2025, and down 199.4% sequentially from $14682.0 in Q4 2025.
RetinalGenix Technologies (RTGN) Net Cash Flow (2020 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 7 years of Net Cash Flow data on file, last reported at -$14594.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow fell 521.29% year-over-year to -$14594.0; the trailing twelve-month figure through Mar 2026 stood at -$3531.0 (up 92.43% YoY), and the FY2025 full-year result was $8714.0, up 43.8% from the prior year.
- Net Cash Flow eased to -$14594.0 in Q1 2026, from $14682.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $50386.0 in Q1 2024 to a low of -$73029.0 in Q4 2024.
- A 5-year average of -$262.35 and a median of -$2349.0 in 2025 frame the typical range for Net Cash Flow.
- Peak annual rise in Net Cash Flow reached 757.32% in 2024, while the deepest fall reached 165875.0% in 2024.
- Tracing RTGN's Net Cash Flow over 5 years: stood at -$3574.0 in 2022, then surged by 98.77% to -$44.0 in 2023, then tumbled by 165875.0% to -$73029.0 in 2024, then soared by 120.1% to $14682.0 in 2025, then sank by 199.4% to -$14594.0 in 2026.
- Business Quant data shows RTGN's Net Cash Flow at -$14594.0 in Q1 2026, $14682.0 in Q4 2025, and -$747.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -1.70 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.11 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 768.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -503.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -500.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 202.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -282.15 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.19 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | -14,594.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,594.00 |
| Mar 31, 2026 | -14,594.00 |
| Dec 31, 2025 | 14,682.00 |
| Dec 31, 2025 | 14,682.00 |
| Sep 30, 2025 | -747.00 |
| Sep 30, 2025 | -747.00 |
| Jun 30, 2025 | -2,872.00 |
| Jun 30, 2025 | -2,872.00 |
| Mar 31, 2025 | -2,349.00 |
| Mar 31, 2025 | -2,349.00 |
| Dec 31, 2024 | -73,029.00 |
| Dec 31, 2024 | -73,029.00 |
| Sep 30, 2024 | -7,824.00 |
| Sep 30, 2024 | -7,824.00 |
| Jun 30, 2024 | 36,527.00 |
| Jun 30, 2024 | 36,527.00 |
| Mar 31, 2024 | 50,386.00 |
| Mar 31, 2024 | 50,386.00 |
| Dec 31, 2023 | -44.00 |
| Dec 31, 2023 | -44.00 |